Prized for their ability to rapidly generate chemical complexity by building new ring systems and stereocentres 1 , cycloaddition reactions have featured in numerous total syntheses 2 and are a key component in the education of chemistry students 3 . Similarly, carbon-carbon (C-C) cross-coupling methods are integral to synthesis because of their programmability, modularity and reliability 4 . Within the area of drug discovery, an overreliance on cross-coupling has led to a disproportionate representation of flat architectures that are rich in carbon atoms with orbitals hybridized in an sp 2 manner 5 . Despite the ability of cycloadditions to introduce multiple carbon sp 3 centres in a single step, they are less used 6 . This is probably because of their lack of modularity, stemming from the idiosyncratic steric and electronic rules for each specific type of cycloaddition. Here we demonstrate a strategy for combining the optimal features of these two chemical transformations into one simple sequence, to enable the modular, enantioselective, scalable and programmable preparation of useful building blocks, natural products and lead scaffolds for drug discovery.
This facilitated both a convergent assembly and a modularity that permitted the rapid exploration of hundreds of analogues.
Here, we sought to combine the innate complexity generation of cycloaddition with the simplicity and modularity of C-C coupling. When applied to structures such as 1, this strategy will permit the rapid generation of analogues, and when applied to medicinal programs such as 2, it will allow for the rapid exploration of otherwise challenging complex chemical space.
Building block 3, of hypothetical value in medicinal chemistry, represents the manifestation of this idea (Fig. 1b ). Although its structure would seem to suggest that it could be formed through a Diels-Alder reaction, the relevant synthetic building blocks, structures 4 and 5, are not electronically matched and therefore one would expect no reaction to take place. Even if a workable enantioselective Diels-Alder reaction could be invented to achieve this transform, the strategy would suffer from a lack of modularity. In order to solve this problem, one could envisage using a hypothetical vicinal dihaloethylene (6) in place of 5, with a fumarate-type dienophile such as 7 serving as a viable synthetic equivalent. The favourable matched electronics of the dienophile should allow for a facile Diels-Alder reaction and subsequent radical cross-coupling (RCC).
To address the enantioselectivity challenge, a combination of transforms was proposed ( Fig. 1c ). Maleic anhydride was chosen as a surrogate for the hypothetical chiral (pseudo)dihalide 6 given its inexpensive nature, ready participation in most cycloaddition modes ([2+1], [2+2], [3+2], [4+2]), and known desymmetrization through chiral Lewisbase-mediated alcoholysis. Our sequence for generating complexity in a modular fashion involves five simple steps: first, cycloaddition to build a scaffold; second, desymmetrization to set absolute stereochemistry; third, RCC to install a new C-C bond; fourth, hydrolysis; and fifth, RCC to forge another new C-C bond. The known versatility of RCC enables a range of functionalities to be installed, from aryl 13 and heteroaryl 14 systems to alkenes 15 , alkynes 16 and alkyl groups 17 . We describe here the preparation of more than 80 synthetic examples and multiple applications, covering a range of natural products (including the synthesis of 1) and real-world examples from industrial settings.
Studies commenced with Diels-Alder [4+2] cycloaddition ( Fig. 2a ), by which a large variety of enantiomerically enriched scaffolds could be produced in a simple modular fashion. First, scaffolds A 1 -A 6 (A 2 being a Diels-Alder adduct and all others being derived from Diels-Alder/hydrogenation) were desymmetrized using Deng's conditions, with either quinine or quinidine used as the Lewis base to deliver mixed acids/esters in excellent enantioselectivity 18 . Next, the mono-acid substrate was subjected to successive Negishi 13, [15] [16] [17] and Suzuki 14 type RCC reactions, depending on starting-material availability or individual preferences. In this manner, some of the most simple and inexpensive Diels-Alder adducts known (A 1 costs US$38.54 per mol and A 2 is US$9.52 per mol) can be transformed into enantioenriched products (11-63) of high value. Indeed, none of these products can at present be prepared using a Diels-Alder reaction (racemic or enantioenriched),
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because in most cases the reaction would require both an electron-rich diene and an electron-rich dienophile and therefore is electronically unfavoured. Furthermore, controlling the chemoselectivity when there are multiple alkenes present in the dienophile is challenging using traditional Diels-Alder chemistry; however, with our method, diverse alkenes and alkynes can be easily installed post-cyclization, with excellent isomeric and geometrical purity (accessing 12, 15, 19, 21, 25 and 31). Typically, scaffolds derived from Diels-Alder adducts A 1 -A 6 have a clear retrosynthetic signature, wherein the electronwithdrawing groups on the dienophile have been homologated, alkylated, or degraded. Therefore, our approach allows access to the previously unexplored chemical space of electron-rich, chiral, 1,2-disubstituted Diels-Alder scaffolds. Using the tactical combination outlined above, a virtually limitless array of substituents is now easily accessed, including halogenated arenes, Lewis-basic hetero cycles, α,β-unsaturated carbonyl groups, cyclopropanes, cyclobutanes, sulfur moieties, and alkenes. In the case of exo and endo isomers A 4 and A 5 (both commercially available), the sequences converged to an identical product using the same coupling partners (27 could be prepared from A 4 or A 5 ).
As shown in Fig. 2b-d , the strategy outlined above could also be applied to [3+2], [2+2] and [2+1] cycloadditions. The vast scope observed with Diels-Alder chemistry was also seen in these cases, accessing substituents such as substituted olefins, terminal alkynes, homoallyl groups, and heterocycles. Pyrrolidine-containing systems could be derived from simple building blocks B 1 and B 2 (accessed through dipolar cycloaddition) 19 to furnish 64-82 with high enantiomeric excess. Quick access to pyrrolidine-containing drug scaffolds is useful: historically these have been extremely relevant to medicinal chemists, with around 40 pharmaceuticals containing this motif 20 . As with the Diels-Alder adducts, none of these structures has been accessed before. Therefore, our approach serves as a modular entry to chiral variants of these coveted scaffolds.
In a similar vein, enantioenriched cyclopentenes were easily produced from palladium-catalysed, trimethylenemethane-based, formal [3+2] cycloaddition adduct B 3 21 . Such structures are highly challenging to access in any other way. Scaffolds C 1 and C 2 , representing entry to [2+2]-derived systems, could be similarly processed. Modular access to enantioenriched cyclobutanes is important and useful given the strict electronic requirements for photochemical cycloaddition and the documented challenge in achieving general asymmetric induction 22 . Access to 1,2-disubstituted cyclobutanes (83-86, derived from C 1 ) compares favourably with photochemical approaches to such systems that frequently give inseparable racemic mixtures of regiomers and diastereomers. Furthermore, access to tetrasubstituted, chiral cyclobutanes is highly useful, as multiple families of dimeric and pseudodimeric cyclobutane natural products contain such structural motifs 23 . Structures such as 87, which would be otherwise extremely difficult to access through conventional photochemistry, can be easily prepared in enantioenriched manner from maleic anhydride heterodimerization adducts such as C 2 . Finally, the strategy outlined above when applied to [2+1] cycloadditions using scaffolds D 1 and D 2 is a major departure from the common retrosynthetic logic normally applied to such structures. Conventional approaches, usually involving late-stage cyclopropanation of an olefin, suffer from lack of enantiocontrol in the absence of directing groups or specialized carbenoid donors and complex catalysts 24 . Structures 94 and 95 (D 2 -derived) are particularly illustrative of this fact: it would be extremely challenging to access either of these in an enantioselective fashion with current synthetic technology (cyclopropanation or C-C cross-coupling). As testament to the power of this strategy to access diverse libraries, we synthesized an additional 48 enantioenriched compounds in a similar manner (see Extended Data Figs. 1 and 2 for details).
To further demonstrate the potential of this approach to simplify synthesis, we present six applications in the total synthesis of natural products and in both early-and late-stage medicinal chemistry programs ( Fig. 3a-f ). As mentioned above, alkaloid 1 has been a popular target of both academic and industrial scientists. Through the application of cycloaddition and cross-coupling, the native carboxylate required for the Diels-Alder reaction can be used directly to produce epibatidine (1) in five steps (for optimization and in-depth analysis of previous approaches, see Supplementary Information) with a 38% gram-scale overall yield Letter reSeArCH (Fig. 3a) . It is worth noting that the key decarboxylative cross-coupling takes place with 95% isolated yield (gram-scale, 72% yield).
Saphris (asenapine, 102; Fig. 3b ), an antipsychotic approved by the US Food and Drug Administration (FDA), is currently marketed as a racemic mixture (although the (+)-isomer has superior pharmacokinetic properties) 25 . This near-symmetric molecule has been challenging to prepare enantioselectively, as the two aromatic systems differ only in one chlorine substituent. It is therefore hard to envisage a cycloaddition that could be rendered enantioselective for the preparation of 102, and only one enantioselective approach has been reported Letter reSeArCH in 16 steps 26 . However, 102 can be prepared in formally six steps, with complete enantiocontrol, from B 2 , through a strategy that could also be used to make an array of near-symmetric analogues. Epothilone-a famous natural product that inhibits the dynamics of cellular microtubules and inspired the FDA-approved medicine Ixabepilone 27 -has been the subject of numerous synthetic studies and analogue campaigns 28 . Intermediate 105 (Fig. 3c ) has been used during Nicolaou's synthesis of a cyclobutyl-containing analogue of epothilone, but required 15 steps (24% overall yield) to be prepared in enantioenriched form from C 1 , via enzymatic desymmetrization and a series of carefully choreographed homologations 28 . Using the same starting material, C 1 , we have prepared intermediate 105 in only eight steps, through sequential desymmetrization, RCC with alkyne 103, hydrolysis, RCC with alkyl zinc 104, protecting-group exchange, and finally hydroboration/oxidation.
Differentially substituted norbornene rings have been shown to be useful phenyl bioisosteres in medicinal chemistry; however, their broad implementation is hindered by a lack of methods for their rapid modular construction (unlike the construction of aryl systems) 29 . In collaboration with Leo Pharma, we prepared a key target for an ongoing program (109; Fig. 3d ) from Diels-Alder adduct 106 via alkene hydration and RCC with the pyrazole-boronic ester 108 in 44% yield. It is worth noting that this is, to our knowledge, the first report of a RCC reaction using a bis(pinacolato)diboron (Bpin) derivative rather than a boronic acid. This advance was achieved using an in situ prepared ate complex, prepared by adding one equivalent of n-BuLi relative to the aryl-Bpin donor 30 . We also used this modification of our Suzuki-RCC protocol to prepare cyclopropanes 91, 92 and 93.
Finally, an ongoing program at Eisai Pharmaceuticals necessitated the preparation of complex scaffold 114 (Fig. 3e ), wherein the key structure-activity relationship to be explored resided at the aryl (green) portion of the molecule. This is a particularly powerful application of the strategy outlined herein, because a carboxylate-needed to achieve the diastereoselective Diels-Alder reaction to construct the decalin framework-served as a gateway for the exploration of chemical space at the desired position. Thus, an asymmetric Diels-Alder reaction using Corey's oxazaborolidine 31 catalyst, followed by functional group manipulations (see Supplementary Information), led to intermediate 112, which could be cross-coupled with boronic acid 113 in a particularly challenging context to deliver 114 and enable biological follow-up.
The strategy outlined here could be useful for more than just forging C-C linkages through cross-coupling. 
and Wolff rearrangements) of intermediate adducts opens up innumerable possibilities for diversification, rendering access to previously inaccessible building blocks (Fig. 3f) . As an example, we used a chiral 2π enamine synthon to prepare 118, an inhibitor of the embryonic ectoderm development (EED) protein (K i = 4 nM), which was previously prepared by AbbVie 32 through a non-modular, racemic [3+2] approach in 1.9% overall yield. Our approach began with intermediate meso scaffold B 2 and used RCC followed by Curtius rearrangement, yielding optically pure 118 in 13% overall yield.
The advance that we have described is largely strategic in nature, and thus the underlying limitations are tied mainly to individual parameters of a particular cycloaddition and ensuing RCC reactions. That said, cis-1,2-disubstituted products are not currently accessible unless downstream isomerization reactions are pursued, which need to be evaluated on a case-by-case basis. Although ligand-controlled RCC reactions might eventually address this issue, in its present form this platform for modular molecular assembly holds great promise for accessing new areas of chemical space. The combination of classic cycloaddition chemistry with newly emerging radical C-C coupling offers a powerful way to repurpose the most classic skeleton-building reactions of organic synthesis, to simplify the enantioselective preparation of building blocks, natural products and medicines.
